DK174599B1 - 3-Substituerede 3-aroyloxy-propanaminer og fremgangsmåde til fremstilling deraf, farmaceutiske præparater og anvendelse af forbindelserne til fremstilling af lægemidler - Google Patents

3-Substituerede 3-aroyloxy-propanaminer og fremgangsmåde til fremstilling deraf, farmaceutiske præparater og anvendelse af forbindelserne til fremstilling af lægemidler Download PDF

Info

Publication number
DK174599B1
DK174599B1 DK198706648A DK664887A DK174599B1 DK 174599 B1 DK174599 B1 DK 174599B1 DK 198706648 A DK198706648 A DK 198706648A DK 664887 A DK664887 A DK 664887A DK 174599 B1 DK174599 B1 DK 174599B1
Authority
DK
Denmark
Prior art keywords
pharmaceutically acceptable
compound
compounds
methyl
acid addition
Prior art date
Application number
DK198706648A
Other languages
Danish (da)
English (en)
Other versions
DK664887A (da
DK664887D0 (da
Inventor
David Taiwai Wong
David Wayne Robertson
Herman Krushinski Joseph Jr
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of DK664887D0 publication Critical patent/DK664887D0/da
Publication of DK664887A publication Critical patent/DK664887A/da
Application granted granted Critical
Publication of DK174599B1 publication Critical patent/DK174599B1/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/28—Halogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK198706648A 1986-12-22 1987-12-17 3-Substituerede 3-aroyloxy-propanaminer og fremgangsmåde til fremstilling deraf, farmaceutiske præparater og anvendelse af forbindelserne til fremstilling af lægemidler DK174599B1 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94512286A 1986-12-22 1986-12-22
US94512286 1986-12-22

Publications (3)

Publication Number Publication Date
DK664887D0 DK664887D0 (da) 1987-12-17
DK664887A DK664887A (da) 1988-06-23
DK174599B1 true DK174599B1 (da) 2003-07-14

Family

ID=25482649

Family Applications (1)

Application Number Title Priority Date Filing Date
DK198706648A DK174599B1 (da) 1986-12-22 1987-12-17 3-Substituerede 3-aroyloxy-propanaminer og fremgangsmåde til fremstilling deraf, farmaceutiske præparater og anvendelse af forbindelserne til fremstilling af lægemidler

Country Status (27)

Country Link
EP (1) EP0273658B1 (de)
JP (1) JP2549681B2 (de)
KR (2) KR880007433A (de)
CN (1) CN1019113B (de)
AR (1) AR243868A1 (de)
AT (1) ATE57924T1 (de)
AU (1) AU591007B2 (de)
CA (1) CA1302421C (de)
CY (2) CY1682A (de)
DE (3) DE122005000002I1 (de)
DK (1) DK174599B1 (de)
EG (1) EG18230A (de)
ES (1) ES2019949B3 (de)
GR (1) GR3001207T3 (de)
HK (1) HK69693A (de)
HU (1) HU206309B (de)
IE (1) IE873449L (de)
IL (1) IL84863A (de)
LU (1) LU91131I2 (de)
MX (1) MX9845A (de)
NL (1) NL300171I2 (de)
NZ (1) NZ222980A (de)
PH (1) PH26556A (de)
PT (1) PT86389B (de)
SG (1) SG114992G (de)
SU (1) SU1598865A3 (de)
ZA (1) ZA879472B (de)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4902710A (en) * 1988-12-14 1990-02-20 Eli Lilly And Company Serotonin and norepinephrine uptake inhibitors
CA2042346A1 (en) * 1990-05-17 1991-11-18 Michael Alexander Staszak Chiral synthesis of 1-aryl-3-aminopropan-1-ols
EP0571685A1 (de) * 1992-05-27 1993-12-01 Novo Nordisk A/S Aryloxyheteroarylpropylamine, ihre Herstellung und Verwendung
US5362886A (en) * 1993-10-12 1994-11-08 Eli Lilly And Company Asymmetric synthesis
TW344661B (en) * 1993-11-24 1998-11-11 Lilly Co Eli Pharmaceutical composition for treatment of incontinence
GB0004149D0 (en) 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel compounds
GB0004153D0 (en) 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel use
GB0004151D0 (en) 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel use
GB0004152D0 (en) * 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel compounds
JP2005500344A (ja) * 2001-07-31 2005-01-06 ファルマシア・アンド・アップジョン・カンパニー ３−アリールオキシ−３−フェニルプロパンアミンを用いた慢性疼痛の治療
SE0102640D0 (sv) 2001-07-31 2001-07-31 Astrazeneca Ab Novel compounds
IL163666A0 (en) 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
US7659409B2 (en) 2002-03-19 2010-02-09 Mitsubishi Chemical Corporation 3-Hydroxy-3-(2-thienyl) propionamides and production method thereof, and production method of 3-amino-1-(2-thienyl)-1-propanols using the same
AU2003221028A1 (en) * 2002-03-19 2003-09-29 Mitsubishi Chemical Corporation 3-hydroxy-3-(2-thienyl)propionamide compound, process for producing the same, and process for producing 3-amino-1-(2-thienyl)-1-propanol compound therefrom
JPWO2003097632A1 (ja) * 2002-05-20 2005-09-15 三菱レイヨン株式会社 プロパノールアミン誘導体、及び３−ｎ−メチルアミノ−１−（２−チエニル）−１−プロパノールの製造方法、並びにプロパノールアミン誘導体の製造方法
DE10235206A1 (de) 2002-08-01 2004-02-19 Basf Ag Verfahren zur Herstellung von (S)-3-Methylmino-1-(thien-2-yl)propan-1-ol
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
GB0229583D0 (en) * 2002-12-19 2003-01-22 Cipla Ltd A process for preparing duloxetine and intermediates for use therein
DE10302595A1 (de) 2003-01-22 2004-07-29 Basf Ag 3-Methylamino-1-(2-thienyl)-1-proganon, seine Herstellung und Verwendung
DE10345772A1 (de) 2003-10-01 2005-04-21 Basf Ag Verfahren zur Herstellung von 3-Methylamino-1-(thien-2-yl)-propan-1-ol
DE102004004719A1 (de) 2004-01-29 2005-08-18 Basf Ag Verfahren zur Herstellung von enantiomerenreinen Aminoalkoholen
CN102627572A (zh) * 2004-02-19 2012-08-08 隆萨股份公司 对映异构体纯的1-取代-3-氨基醇的制备方法
DE102004022686A1 (de) 2004-05-05 2005-11-24 Basf Ag Verfahren zur Herstellung optisch aktiver Alkohole
GB0410470D0 (en) * 2004-05-11 2004-06-16 Cipla Ltd Pharmaceutical compound and polymorphs thereof
AR049401A1 (es) 2004-06-18 2006-07-26 Novartis Ag Aza-biciclononanos
GB0415746D0 (en) 2004-07-14 2004-08-18 Novartis Ag Organic compounds
EP1784381A1 (de) 2004-08-26 2007-05-16 Neurosearch A/S Neue substituierte aryloxyalkylamine und deren verwendung als monoamin neurotransmitter wiederaufnahmehemmer
EP1730132A2 (de) * 2004-12-23 2006-12-13 Teva Pharmaceutical Industries Ltd Verfahren zur herstellung pharmazeutisch unbedenklicher salze von duloxetin und zwischenprodukten davon
TW200639162A (en) 2005-03-14 2006-11-16 Teva Pharma Pure duloxetine hydrochloride
GB0507298D0 (en) 2005-04-11 2005-05-18 Novartis Ag Organic compounds
CN101495184A (zh) 2005-07-15 2009-07-29 Amr科技公司 芳基和杂芳基取代的四氢苯并氮杂及其在阻断去甲肾上腺素多巴胺和血清素的重摄取中的应用
DE102005044736A1 (de) 2005-09-19 2007-03-22 Basf Ag Neue Dehydrogenasen, deren Derivate und ein Verfahren zur Herstellung von optisch aktiven Alkanolen
US7842717B2 (en) 2005-09-22 2010-11-30 Teva Pharmaceutical Industries Ltd. DNT-maleate and methods of preparation thereof
ITMI20051970A1 (it) 2005-10-18 2007-04-19 Solmag S P A Processo per la preparazione di eteri misti derivanti dall'inaftolo e intermedi di forme cristalline definite di + e - duloxetina
DE602006009138D1 (de) * 2005-11-30 2009-10-22 Hoffmann La Roche 3-amino-2-arylpropylazaindole und anwendungen davon
US7759500B2 (en) 2005-12-05 2010-07-20 Teva Pharmaceutical Industries Ltd. 2-(N-methyl-propanamine)-3-(2-naphthol)thiophene, an impurity of duloxetine hydrochloride
GB0525673D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0525672D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
DE102005062662A1 (de) 2005-12-23 2007-06-28 Basf Ag Verfahren zur Herstellung optisch aktiver Alkohole
DE102005062661A1 (de) 2005-12-23 2007-08-16 Basf Ag Verfahren zur Herstellung von optisch aktivem (1S)-3-Chlor-(-thien-2-yl)-propan-1-ol
CZ299270B6 (cs) 2006-01-04 2008-06-04 Zentiva, A. S. Zpusob výroby hydrochloridu (S)-N-methyl-3-(1-naftyloxy)-3-(2-thienyl)propylaminu
WO2007077580A2 (en) 2006-01-06 2007-07-12 Msn Laboratories Limited Improved process for pure duloxetine hydrochloride
ATE552250T1 (de) 2006-12-22 2012-04-15 Synthon Bv Verfahren zur herstellung von duloxetin und verwandten verbindungen
AU2009234322B2 (en) * 2008-04-11 2014-12-04 Nektar Therapeutics Oligomer-aryloxy-substituted propanamine conjugates
EP2133072A1 (de) 2008-06-13 2009-12-16 KRKA, D.D., Novo Mesto Magenresistente orale pharmazeutische Zusammensetzungen mit Duloxetin oder pharmazeutisch zulässigen Derivaten
CN101613347B (zh) * 2008-06-23 2012-07-04 中国人民解放军军事医学科学院毒物药物研究所 胺类化合物及其医药用途
HU230480B1 (hu) * 2008-07-25 2016-07-28 Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság Eljárás N-metil-ariloxi-propánamin származékok előállítására
WO2010025287A2 (en) 2008-08-27 2010-03-04 Codexis, Inc. Ketoreductase polypeptides for the production of 3-aryl-3-hydroxypropanamine from a 3-aryl-3-ketopropanamine
SI2329013T1 (sl) 2008-08-27 2016-03-31 Codexis, Inc. Polipeptidi ketoreduktaze za proizvodnjo 3-aril-3-hidroksipropanamina iz 3-aril-3-ketopropanamina
CA2760837C (en) 2009-05-12 2018-04-03 Albany Molecular Research, Inc. 7-([1,2,4]triazolo[1,5-.alpha.]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof
US8815894B2 (en) 2009-05-12 2014-08-26 Bristol-Myers Squibb Company Crystalline forms of (S)-7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof
CZ304602B6 (cs) 2009-09-02 2014-07-30 Zentiva, K. S. Způsob krystalizace hydrochloridu (S)-N-methyl-3-(1-naftyloxy)-3-(2-thienyl)propylaminu (hydrochloridu duloxetinu)
EP2377525A1 (de) 2010-03-26 2011-10-19 Laboratorios del Dr. Esteve S.A. Enterische Duloxetin-Tabletten
WO2011128370A1 (en) 2010-04-13 2011-10-20 Krka, D.D., Novo Mesto Synthesis of duloxetine and/or pharmaceutically acceptable salts thereof
US9045468B2 (en) 2010-08-17 2015-06-02 Albany Molecular Research, Inc. 2,5-methano- and 2,5-ethano-tetrahydrobenzazepine derivatives and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
EP2508519A1 (de) * 2011-04-07 2012-10-10 Bioindustria Laboratorio Italiano Medicinali S.p.A In forma abbreviata Bioindustria L.I.M. S.p.A. Verfahren zur Herstellung von Duloxetin und seinem Hydrochloridsalz
GR1007725B (el) 2011-10-17 2012-10-18 Φαρματεν Αβεε, Μεθοδος δια την παρασκευη υδροχλωρικης ντουλοξετινης υψηλης καθαροτητας
PL224543B1 (pl) 2013-08-21 2017-01-31 Pabianickie Zakłady Farm Polfa Spółka Akcyjna Dojelitowa tabletka duloksetyny
US9668975B2 (en) 2014-10-14 2017-06-06 PharmaDax Inc. Method of preparing drug agglomerate
CN105777706B (zh) 2014-12-25 2019-08-23 江苏恩华药业股份有限公司 一种3-[(苯并[d][1, 3]二氧戊环-4-基)-氧基]-3-芳基丙胺类化合物及其应用
JP2016222628A (ja) * 2015-06-03 2016-12-28 株式会社トクヤマ デュロキセチン塩酸塩の製造方法
JP6182183B2 (ja) * 2015-07-07 2017-08-16 東和薬品株式会社 デュロキセチン塩基及びデュロキセチン塩酸塩の製造方法
CN106349211B (zh) * 2016-08-26 2020-10-16 江苏恩华药业股份有限公司 2-甲基-3-芳氧基-3-杂芳基丙胺类化合物及应用
EP3339304A1 (de) * 2016-12-20 2018-06-27 Laboratorios del Dr. Esteve, S.A. Neue chinolin- und isochinolinderivate zur behandlung von schmerzen und schmerzbedingten leiden
EP3971181A4 (de) * 2019-05-16 2023-11-08 Shanghai Leado Pharmatech Co. Ltd. 3-aryloxyl-3-fünfgliedrige heteroarylpropylaminverbindung sowie kristallform und deren verwendung

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2842555A (en) * 1954-07-27 1958-07-08 Burroughs Wellcome Co Method of preparing quaternary salts of amino carbinols
AT255400B (de) * 1965-03-22 1967-07-10 Chemie Linz Ag Verfahren zur Herstellung von neuen basischen Äthern
US3423510A (en) * 1966-08-31 1969-01-21 Geigy Chem Corp 3-(p-halophenyl) - 3 - (2'-pyridyl-n-methylpropylamine for the treatment of depression
US4018895A (en) * 1974-01-10 1977-04-19 Eli Lilly And Company Aryloxyphenylpropylamines in treating depression
FR2482956A1 (fr) * 1980-05-22 1981-11-27 Synthelabo Cyclohexylalkylamines, leurs procedes de preparation et leur application en therapeutique

Also Published As

Publication number Publication date
NL300171I2 (nl) 2005-06-01
AR243868A1 (es) 1993-09-30
CA1302421C (en) 1992-06-02
CY1682A (en) 1993-10-10
EP0273658B1 (de) 1990-10-31
AU591007B2 (en) 1989-11-23
EP0273658A1 (de) 1988-07-06
DK664887A (da) 1988-06-23
ZA879472B (en) 1989-08-30
MX9845A (es) 1993-12-01
JP2549681B2 (ja) 1996-10-30
IL84863A0 (en) 1988-06-30
ATE57924T1 (de) 1990-11-15
LU91131I2 (fr) 2005-03-29
KR880007433A (ko) 1988-08-27
NL300171I1 (nl) 2005-04-01
CY2005001I1 (el) 2009-11-04
ES2019949B3 (es) 1991-07-16
CN1019113B (zh) 1992-11-18
JPS63185946A (ja) 1988-08-01
HU206309B (en) 1992-10-28
IL84863A (en) 1992-03-29
CN87108175A (zh) 1988-07-06
SG114992G (en) 1993-01-29
HUT47561A (en) 1989-03-28
PT86389B (pt) 1990-11-20
HK69693A (en) 1993-07-30
GR3001207T3 (en) 1992-07-30
DK664887D0 (da) 1987-12-17
DE3765919D1 (de) 1990-12-06
KR960003808B1 (ko) 1996-03-22
AU8266087A (en) 1988-06-23
IE873449L (en) 1988-06-22
DE122005000002I1 (de) 2005-05-12
PT86389A (en) 1988-01-01
SU1598865A3 (ru) 1990-10-07
NZ222980A (en) 1989-11-28
PH26556A (en) 1992-08-19
DE122005000002I2 (de) 2006-08-24
CY2005001I2 (el) 2009-11-04
EG18230A (en) 1992-10-30

Similar Documents

Publication Publication Date Title
DK174599B1 (da) 3-Substituerede 3-aroyloxy-propanaminer og fremgangsmåde til fremstilling deraf, farmaceutiske præparater og anvendelse af forbindelserne til fremstilling af lægemidler
DE68913930T2 (de) Serotonin- und Norepinephrin-Aufnahme-Inhibitoren.
US5023269A (en) 3-aryloxy-3-substituted propanamines
EP0288188B1 (de) 1-Phenyl-3-naphthalenyloxy-propanamine
JP2000505795A (ja) 置換シクロアザンから誘導された新規芳香族ピペラジン、それらの調製法、医薬組成物、および薬剤としての使用
EP1337528B1 (de) Benzothiophenderivate, verhahren zu ihrer herstellung und ihre verwendung
EP0369685B1 (de) Fluoxetin-Analogon
JPH02268151A (ja) 環置換された２―アミノ―１，２，３，４―テトラヒドロナフタレンおよび３―アミノクロマン類
JPH02289586A (ja) １Ｈ，３Ｈ‐ピロロ［１，２‐ｃ］チアゾール‐７‐カルボキサミド誘導体、それらの製造法及び製薬学的組成物
KR20000075697A (ko) 5-ｈｔ2ａ-길항제로서의 옥사졸리딘
MXPA06013520A (es) Tetrahironaftilpiperazinas como antagonistas, agonistas inversos y agonistas parciales de 5-ht1b.
Carter et al. Analogs of oxybutynin. Synthesis and antimuscarinic and bladder activity of some substituted 7-amino-1-hydroxy-5-heptyn-2-ones and related compounds
US5177077A (en) 1,4-disubstituted piperazines
EP1020466B1 (de) 5,11-DIHYDROBENZ[b,e][1,4]OXAZEPIN-DERIVATE UND DIESE ENTHALTENDE MEDIZINISCHE ZUBEREITUNGEN
JPH09506638A (ja) アリールおよびヘテロアリールアルコキシナフタレン誘導体
EP0318234B1 (de) Selektive Sertonin-Aufnahme-Inhibitoren
FR2761064A1 (fr) Piperazines derivees d'amines cycliques, leur preparation et leur application comme medicaments
DK175352B1 (da) Fremgangsmåde til fremstilling af 4-phenylpiperidinderivater
JPH0550517B2 (de)
JPS5833872B2 (ja) ヘキサヒドロジベンゾフラン −３− オンノシンキナユウドウタイオヨビ ソノエンルイノセイゾウホウ
MXPA97003899A (en) Arilacrilam derivative

Legal Events

Date Code Title Description
CTFF Application for supplementary protection certificate (spc) filed

Spc suppl protection certif: CA 2005 00002

Filing date: 20050131

Expiry date: 20121217

CTFG Supplementary protection certificate (spc) issued

Free format text: PRODUCT NAME: DULOXETIN, DULOXETINHYDROCHLORID

Spc suppl protection certif: CA 2005 00002

Filing date: 20050131

PUP Patent expired